RE:RE:RE:RE:RE:BEAT THE SHORTIES ...The partnership between CREO and CCS will bring new product offerings to the USA market in early 2019. For CardioComm Solutions, this will generate multiple new revenue streams resulting from the licensing of CardioComm's GEMS cloud and Smart phone app ECG management tools, the purchase of GEMS compatible OTC and Rx ECG devices and a fee-for-use based on CardioComm's SMART Monitoring ECG reading service Both companies expect that at least 30% of CREO patients will require ECG monitoring ranging from routine baseline recordings to regular daily monitoring for prolonged periods of time. The first phase of technology integration is expected to be completed in Q1 2019, followed by the full launch of the ECG services across the CREO platform.